Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
GSK announced today that the U.S. Food and Drug Administration (FDA) has approved its pandemic Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (also referred to as Q-Pa...
Read more -
GSK Responds to FDA Decision on Avandia (rosiglitazone)
GSK announced today that the U.S. Food and Drug Administration (FDA) has eased restrictions on patient access to Avandia (rosiglitazone), following an FDA Advisory Committee rev...
Read more -
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending ...
Read more -
GSK and Amicus Therapeutics announce revised Fabry agreement
GSK and Amicus Therapeutics today announced that Amicus has obtained global rights to develop and commercialise the investigational pharmacological chaperone migalastat HCl as a...
Read more -
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD
GSK and Theravance, Inc. announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®.
Read more -
Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children
A simple low-cost device that helps newborn babies to breathe and has the potential to transform the life chances for thousands of African babies has been awarded the highest fu...
Read more -
GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease
Study did not meet the primary endpoint measure.
Read more -
GSK names inaugural winners in unique competition for academic drug hunters
GSK today announced the selection of eight winners in its first Discovery Fast Track competition, designed to translate academic research into starting points for new potential ...
Read more -
GSK announces new apprentice and graduate engineering opportunities in the UK during Tomorrow’s Engineers Week
GSK today announced the recruitment of 140 new apprentices over the next two years in the UK - of which a third will be in engineering.
Read more -
GSK announces data to support Cervarix® two-dose schedule for the prevention of cervical cancer in 9-14 year old girls
GSK today announced the results of a Phase III study of its HPV vaccine, Cervarix.
Read more -
New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs
GSK and the Bill & Melinda Gates Foundation (BMGF) today announced the launch of a new joint initiative that will endeavour to make vaccines more resistant to heat, thus reducin...
Read more -
GSK to create a new Centre of Excellence for Sustainable Chemistry in Brazil
GSK today announced it has formed a new collaboration with the São Paulo Research Foundation (FAPESP) to create a new Centre of Excellence for Sustainable Chemistry in Brazil.
Read more -
ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV Healthcare today announced the submission of a regulatory application in Europe for its investigational single-tablet regimen (STR) combining dolutegravir (DTG), abacavir (...
Read more -
Synflorix™ receives positive opinion from the CHMP in Europe for additional pneumonia indication
GSK today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an additional indicatio...
Read more -
GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma
GSK today announced the submission of a New Drug Application in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using th...
Read more -
Results announcement for the third quarter 2013
GSK announces Q3 core EPS growth of 16% and dividend of 19p
Read more -
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV Healthcare today announced the submission of a regulatory application in the US for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lam...
Read more -
Regulatory update – GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab A/S announced today the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for the use of Arzerra® (ofatumuma...
Read more -
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young childr...
Read more -
Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab A/S announced today the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in com...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
